These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9630457)

  • 1. Toxicology and pharmacokinetics of DT388-GM-CSF, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor (GM-CSF) in C57BL/6 mice.
    Hall PD; Kreitman RJ; Willingham MC; Frankel AE
    Toxicol Appl Pharmacol; 1998 May; 150(1):91-7. PubMed ID: 9630457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicology and pharmacokinetics of DTGM, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor, in cynomolgus monkeys.
    Hotchkiss CE; Hall PD; Cline JM; Willingham MC; Kreitman RJ; Gardin J; Latimer A; Ramage J; Feely T; DeLatte S; Tagge EP; Frankel AE
    Toxicol Appl Pharmacol; 1999 Jul; 158(2):152-60. PubMed ID: 10406930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DT388-GM-CSF, a novel fusion toxin consisting of a truncated diphtheria toxin fused to human granulocyte-macrophage colony-stimulating factor, prolongs host survival in a SCID mouse model of acute myeloid leukemia.
    Hall PD; Willingham MC; Kreitman RJ; Frankel AE
    Leukemia; 1999 Apr; 13(4):629-33. PubMed ID: 10214872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF.
    Frankel AE; Hall PD; McLain C; Safa AR; Tagge EP; Kreitman RJ
    Bioconjug Chem; 1998; 9(4):490-6. PubMed ID: 9667951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia.
    Frankel AE; Lilly M; Kreitman R; Hogge D; Beran M; Freedman MH; Emanuel PD; McLain C; Hall P; Tagge E; Berger M; Eaves C
    Blood; 1998 Dec; 92(11):4279-86. PubMed ID: 9834234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variable cytotoxicity of diphtheria toxin 388-granulocyte-macrophage colony-stimulating factor fusion protein for acute myelogenous leukemia stem cells.
    Feuring-Buske M; Frankel A; Gerhard B; Hogge D
    Exp Hematol; 2000 Dec; 28(12):1390-400. PubMed ID: 11146161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of apoptosis in multidrug-resistant and radiation-resistant acute myeloid leukemia cells by a recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor.
    Perentesis JP; Waddick KG; Bendel AE; Shao Y; Warman BE; Chandan-Langlie M; Uckun FM
    Clin Cancer Res; 1997 Mar; 3(3):347-55. PubMed ID: 9815691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin-granulocyte-macrophage colony-stimulating factor fusion protein.
    Hogge DE; Willman CL; Kreitman RJ; Berger M; Hall PD; Kopecky KJ; McLain C; Tagge EP; Eaves CJ; Frankel AE
    Blood; 1998 Jul; 92(2):589-95. PubMed ID: 9657759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant toxins containing human granulocyte-macrophage colony-stimulating factor and either pseudomonas exotoxin or diphtheria toxin kill gastrointestinal cancer and leukemia cells.
    Kreitman RJ; Pastan I
    Blood; 1997 Jul; 90(1):252-9. PubMed ID: 9207460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia.
    Frankel AE; Powell BL; Hall PD; Case LD; Kreitman RJ
    Clin Cancer Res; 2002 May; 8(5):1004-13. PubMed ID: 12006512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of the apoptotic response of human myeloid leukemia cells to a diphtheria toxin granulocyte-macrophage colony-stimulating factor fusion protein.
    Frankel AE; Hall PD; Burbage C; Vesely J; Willingham M; Bhalla K; Kreitman RJ
    Blood; 1997 Nov; 90(9):3654-61. PubMed ID: 9345050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody response to DT-GM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte-macrophage colony stimulating factor (GM), during a phase I trial of patients with relapsed or refractory acute myeloid leukemia.
    Hall PD; Virella G; Willoughby T; Atchley DH; Kreitman RJ; Frankel AE
    Clin Immunol; 2001 Aug; 100(2):191-7. PubMed ID: 11465948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo biotherapy of HL-60 myeloid leukemia with a genetically engineered recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor.
    Perentesis JP; Gunther R; Waurzyniak B; Yanishevski Y; Myers DE; Ek O; Messinger Y; Shao Y; Chelstrom LM; Schneider E; Evans WE; Uckun FM
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2217-27. PubMed ID: 9815618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-level expression and purification of the recombinant diphtheria fusion toxin DTGM for PHASE I clinical trials.
    Frankel AE; Ramage J; Latimer A; Feely T; Delatte S; Hall P; Tagge E; Kreitman R; Willingham M
    Protein Expr Purif; 1999 Jun; 16(1):190-201. PubMed ID: 10336877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced ceramide generation and induction of apoptosis in human leukemia cells exposed to DT(388)-granulocyte-macrophage colony-stimulating factor (GM-CSF), a truncated diphtheria toxin fused to human GM-CSF.
    Senchenkov A; Han TY; Wang H; Frankel AE; Kottke TJ; Kaufmann SH; Cabot MC
    Blood; 2001 Sep; 98(6):1927-34. PubMed ID: 11535531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials.
    Urieto JO; Liu T; Black JH; Cohen KA; Hall PD; Willingham MC; Pennell LK; Hogge DE; Kreitman RJ; Frankel AE
    Protein Expr Purif; 2004 Jan; 33(1):123-33. PubMed ID: 14680969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Experimental study of 131I-labeled granulocyte macrophage colony-stimulating factor in SCID mouse-acute myeloid leukemia model].
    Deng YJ; Lou SF; Xu YZ
    Zhonghua Xue Ye Xue Za Zhi; 2007 Jan; 28(1):33-6. PubMed ID: 17649724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor and Ara-C exert synergistic toxicity against human AML HL-60 cells.
    Kim CN; Bhalla K; Kreitman RJ; Willingham MC; Hall P; Tagge EP; Jia T; Frankel AE
    Leuk Res; 1999 Jun; 23(6):527-38. PubMed ID: 10374846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
    Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Production of recombinant DTctGMCSF fusion toxin in a baculovirus expression vector system for biotherapy of GMCSF-receptor positive hematologic malignancies.
    Williams MD; Rostovtsev A; Narla RK; Uckun FM
    Protein Expr Purif; 1998 Jul; 13(2):210-21. PubMed ID: 9675065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.